• Company
• Domestic COVID-19 vaccine developers at a crossroads
• by Kim, Jin-Gu May 11, 2022 05:55am

• Policy
• “Dualized RWD collection for Kymriah is inefficient”
• by Lee, Tak-Sun May 11, 2022 05:55am

• Policy
• Reblozyl was approved after 1 yr of designation of rare drug
• by Lee, Hye-Kyung May 11, 2022 05:55am

• Policy
• President Yoon said he was grateful to the people
• by Lee, Jeong-Hwan May 11, 2022 05:55am

• Company
• Kakao is throwing the hat into the healthcare business
• by Kim, Jin-Gu May 10, 2022 06:14pm

• Company
• Koselugo reattempts insurance benefit in neurofibromatosis
• by Eo, Yun-Ho May 10, 2022 06:07am

• Company
• Powder-type child antipyretic analgesics have been released
• by May 10, 2022 06:07am

• Company
• Sales of generic for Galvus are not affected
• by Kim, Jin-Gu May 10, 2022 06:07am

• Product
• Unsure efficacy of Alzheimer's drug aducanumab
• by Choi-sun May 10, 2022 06:07am

• Company
• The diagnosis of rheumatoid arthritis has been activated
• by Eo, Yun-Ho May 9, 2022 06:04am